Ugur Eskiocak
Affiliations: | Associate Director, In Vivo Immunopharmacology | Compass Therapeutics | |
| 2011-2016 | Children's Research Institute | University of Texas Southwestern Medical Center at Dallas, Dallas, TX, United States |
Google:
"Ugur Eskiocak"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Sean J. Morrison | post-doc | 2011-2016 | University of Texas Southwestern Medical Center at Dallas |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Payne KK, Mine JA, Biswas S, et al. (2020) BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells. Science (New York, N.Y.). 369: 942-949 |
| Gao X, Zhang Z, Mashimo T, et al. (2020) Gliomas Interact with Non-glioma Brain Cells via Extracellular Vesicles. Cell Reports. 30: 2489-2500.e5 |
| Kasitinon SY, Eskiocak U, Martin M, et al. (2019) TRPML1 Promotes Protein Homeostasis in Melanoma Cells by Negatively Regulating MAPK and mTORC1 Signaling. Cell Reports. 28: 2293-2305.e9 |
| Eskiocak U, Guzman W, Daly T, et al. (2019) Abstract 3239: CTX-5861 mediated SIRPα blockade combines with tumor targeting antibodies, checkpoint blockade and/or CD137 agonism to elicit curative anti-tumor activity in syngeneic mouse models Cancer Research. 79: 3239-3239 |
| Eskiocak B, McMillan E, Mendiratta S, et al. (2017) Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discovery |
| Frankel AE, Eskiocak U, Gill JG, et al. (2017) Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients. Neoplasia (New York, N.Y.). 19: 255-260 |
| Potu H, Peterson LF, Kandarpa M, et al. (2017) Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma. Nature Communications. 8: 14449 |
| Zhang L, Theodoropoulos PC, Eskiocak U, et al. (2016) Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer. Science Translational Medicine. 8: 361ra140 |
| Eskiocak U, Ramesh V, Gill JG, et al. (2016) Erratum: Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma. Nature Communications. 7: 13080 |
| Eskiocak U, Ramesh V, Gill JG, et al. (2016) Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma. Nature Communications. 7: 12336 |